Unique results for cancer drug
Unique results for cancer drug presented in Cambridge
Results from a Swedish study shows that two thirds of the dogs that took part in the research recovered. The unique results were presented in Cambridge on Sunday.
The study was performed by the pharmaceutical company Oasmia Pharmaceutical in co-operation with the Swedish University of Agricultural Studies in Uppsala. It is the first successful study using the cancer drug paclitaxel in dogs. Earlier attempts published have failed because of severe side-effects.
The new pharmaceutical Paclical® Vet containing paclitaxel is given as an infusion for 15 minutes every third week until the tumour decreased significantly in size or vanished completely.
- It really is astonishing results that has exceeded all my expectations, says veterinarian Patricio Rivera who has worked with the dogs at the Department of Clinical Sciences at SLU.
The results from the study was presented at the annual veterinary oncological conference in Cambridge, England, shows that earlier incurable tumour diseases in dogs can now be treated. The interest among the participating veterinarians was great.
The company Oasmia and CEO Julian Aleksov counts on a big impact among veterinarians world-wide. The results improve the company's product portfolio, especially the pharmaceutical Paclical® for human use.
- We expect that Paclical® Vet will be registered during 2008 as the first veterinary cancer drug in the world, Aleksov says.
There are over 140 million dogs in the EU and USA. Approximately 50% of all dogs older than 6 years develop cancer in some form.
Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases.
The press release is available in PDF-format here.
